FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2940254522> ?p ?o ?g. }

• W2940254522 abstract "Different studies suggest that fulvestrant 500 mg every 28 days (HD-FUL) could be an active treatment in HR+ advanced breast cancer (ABC) patients even treated with aromatase inhibitors in the adjuvant setting. The aim of this analysis is to describe the outcome of ABC patients treated with HD-FUL as first-line treatment in terms of median duration of treatment and the overall response rate in a real-world setting.For the purpose of the present analysis, we considered two data sets of HR+ ABC patients collected in Italy between 2012 and 2015 (EVA and GIM-13 AMBRA studies).Eighty-one and 91 patients have been identified from the two data sets. The median age was 63 years (range 35-82) for the EVA and 57.8 years (range 35.0-82.3) for the AMBRA patients. ORRs were 23.5 and 24.3% in the whole population, 26.9% in the patients with bone only, and 21.8 and 21.4% in those with visceral metastases. The median duration of HD-FUL was 11.6 months (range 1-48) and 12.4 months (range 2.9-70.0) in the two data sets, respectively.These data suggest that HD-FUL should still continue to play a significant role as first-line therapy in HR+ ABC patients." @default.
• W2940254522 created "2019-04-25" @default.
• W2940254522 creator A5001201465 @default.
• W2940254522 creator A5002123343 @default.
• W2940254522 creator A5003661852 @default.
• W2940254522 creator A5004098731 @default.
• W2940254522 creator A5007382846 @default.
• W2940254522 creator A5008840195 @default.
• W2940254522 creator A5009199625 @default.
• W2940254522 creator A5010531543 @default.
• W2940254522 creator A5010972450 @default.
• W2940254522 creator A5011753332 @default.
• W2940254522 creator A5013748999 @default.
• W2940254522 creator A5019107001 @default.
• W2940254522 creator A5020078965 @default.
• W2940254522 creator A5020344479 @default.
• W2940254522 creator A5020943144 @default.
• W2940254522 creator A5025684262 @default.
• W2940254522 creator A5027075905 @default.
• W2940254522 creator A5030013928 @default.
• W2940254522 creator A5031414207 @default.
• W2940254522 creator A5032713092 @default.
• W2940254522 creator A5032747123 @default.
• W2940254522 creator A5033082338 @default.
• W2940254522 creator A5034345931 @default.
• W2940254522 creator A5035108656 @default.
• W2940254522 creator A5035471408 @default.
• W2940254522 creator A5039478541 @default.
• W2940254522 creator A5041363231 @default.
• W2940254522 creator A5041668420 @default.
• W2940254522 creator A5042989547 @default.
• W2940254522 creator A5045396654 @default.
• W2940254522 creator A5045496715 @default.
• W2940254522 creator A5046176016 @default.
• W2940254522 creator A5048969389 @default.
• W2940254522 creator A5050421775 @default.
• W2940254522 creator A5054331746 @default.
• W2940254522 creator A5057001950 @default.
• W2940254522 creator A5058537459 @default.
• W2940254522 creator A5063676677 @default.
• W2940254522 creator A5066455981 @default.
• W2940254522 creator A5067997872 @default.
• W2940254522 creator A5068234157 @default.
• W2940254522 creator A5068497911 @default.
• W2940254522 creator A5070419785 @default.
• W2940254522 creator A5074033106 @default.
• W2940254522 creator A5074479074 @default.
• W2940254522 creator A5074537397 @default.
• W2940254522 creator A5077078360 @default.
• W2940254522 creator A5077623457 @default.
• W2940254522 creator A5079244843 @default.
• W2940254522 creator A5086518280 @default.
• W2940254522 creator A5091765229 @default.
• W2940254522 date "2019-04-17" @default.
• W2940254522 modified "2023-10-11" @default.
• W2940254522 title "Is There Still a Role for Endocrine Therapy Alone in HR+/HER2– Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies" @default.
• W2940254522 cites W1540562253 @default.
• W2940254522 cites W1563500585 @default.
• W2940254522 cites W1565310327 @default.
• W2940254522 cites W1985390824 @default.
• W2940254522 cites W2012977771 @default.
• W2940254522 cites W2105084636 @default.
• W2940254522 cites W2134839096 @default.
• W2940254522 cites W2139726760 @default.
• W2940254522 cites W2140442588 @default.
• W2940254522 cites W2140811091 @default.
• W2940254522 cites W2142334766 @default.
• W2940254522 cites W2528767298 @default.
• W2940254522 cites W2558360748 @default.
• W2940254522 cites W2560635244 @default.
• W2940254522 cites W2621250710 @default.
• W2940254522 cites W2734686666 @default.
• W2940254522 cites W2763875663 @default.
• W2940254522 cites W3016908890 @default.
• W2940254522 doi "https://doi.org/10.1159/000495469" @default.
• W2940254522 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7098305" @default.
• W2940254522 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32231495" @default.
• W2940254522 hasPublicationYear "2019" @default.
• W2940254522 type Work @default.
• W2940254522 sameAs 2940254522 @default.
• W2940254522 citedByCount "0" @default.
• W2940254522 crossrefType "journal-article" @default.
• W2940254522 hasAuthorship W2940254522A5001201465 @default.
• W2940254522 hasAuthorship W2940254522A5002123343 @default.
• W2940254522 hasAuthorship W2940254522A5003661852 @default.
• W2940254522 hasAuthorship W2940254522A5004098731 @default.
• W2940254522 hasAuthorship W2940254522A5007382846 @default.
• W2940254522 hasAuthorship W2940254522A5008840195 @default.
• W2940254522 hasAuthorship W2940254522A5009199625 @default.
• W2940254522 hasAuthorship W2940254522A5010531543 @default.
• W2940254522 hasAuthorship W2940254522A5010972450 @default.
• W2940254522 hasAuthorship W2940254522A5011753332 @default.
• W2940254522 hasAuthorship W2940254522A5013748999 @default.
• W2940254522 hasAuthorship W2940254522A5019107001 @default.
• W2940254522 hasAuthorship W2940254522A5020078965 @default.
• W2940254522 hasAuthorship W2940254522A5020344479 @default.
• W2940254522 hasAuthorship W2940254522A5020943144 @default.
• W2940254522 hasAuthorship W2940254522A5025684262 @default.
• W2940254522 hasAuthorship W2940254522A5027075905 @default.
• W2940254522 hasAuthorship W2940254522A5030013928 @default.

• next